MONACO, April 4, 2013 (GLOBE NEWSWIRE) -- myoscience, inc. presents European launch of its ground breaking toxin-free treatment, iovera˚, at The Anti-Aging Medicine World Congress (AMWC) in Monaco. iovera˚ is a new tool for aesthetic physicians for the treatment of dynamic facial lines. iovera˚ immediately reduces the appearance of forehead lines using only the body's natural response to cold.
iovera˚ targets facial lines precisely using Focused Cold TherapyTM, an advanced technology that works immediately and temporarily relaxes facial muscles that cause wrinkles without leaving any toxins or chemicals behind in the body. Many people who want to treat their dynamic facial lines but are uncomfortable with previously available treatments now have a new option with iovera˚.
Clint Carnell, CEO of myoscience, is excited to see iovera˚ come alive in the hands of physicians in Europe. "We developed iovera˚ in partnership with some of the world's leading physicians. There is powerful consumer demand for a wrinkle solution that has no toxins and no wait for results, so there's no worry for patients about getting back to their regular lifestyle."
Dr. Jonathan Sykes, Director of Facial Plastic Surgery, UC Davis Medical Center, California, who will present about iovera˚ at AMWC says, "Recent in-clinic market research of nearly 4,000 patients demonstrates that the offer of an effective toxin-free, minimally invasive option for dynamic forehead lines is a very attractive proposition. iovera˚ not only appeals to consumers new to aesthetic procedures, but also to existing patients." He adds, "iovera˚ is an exciting breakthrough in medical aesthetics because it will create new opportunities by opening clinic doors to a previously unseen consumer group seeking an effective, quick, toxin-free treatment option."
iovera˚ will be available first to physicians in the UK, Germany, the Netherlands, Belgium and France, with planned expansion into the rest of the EU throughout 2013.
Silicon Valley, California-based myoscience is a privately-held medical device company committed to making its platform technology, Focused Cold TherapyTM, the standard of care for the treatment of peripheral nerve conditions. Focused Cold Therapy is currently approved in Europe and Canada for temporary wrinkle reduction, temporary pain reduction and treatment of dermatologic conditions. The myoscience technology has also been cleared in the United States for use in pain management and general surgical use. For more information, please visit www.myoscience.com.
The myoscience logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=13581
CONTACT: Alexandra Mack 650-421-0609 email@example.com